You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Details for New Drug Application (NDA): 208036


✉ Email this page to a colleague

« Back to Dashboard


NDA 208036 describes VARIBAR THIN LIQUID, which is a drug marketed by Bracco and is included in one NDA. It is available from one supplier. Additional details are available on the VARIBAR THIN LIQUID profile page.

The generic ingredient in VARIBAR THIN LIQUID is barium sulfate. Two suppliers are listed for this compound. Additional details are available on the barium sulfate profile page.
Summary for 208036
Tradename:VARIBAR THIN LIQUID
Applicant:Bracco
Ingredient:barium sulfate
Patents:0
Pharmacology for NDA: 208036
Mechanism of ActionX-Ray Contrast Activity
Medical Subject Heading (MeSH) Categories for 208036
Contrast Media
Suppliers and Packaging for NDA: 208036
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
E-Z-CAT DRY barium sulfate FOR SUSPENSION;ORAL 208036 NDA E-Z-EM Canada Inc 32909-105 32909-105-10 24 BOTTLE, PLASTIC in 1 CASE (32909-105-10) / 148 g in 1 BOTTLE, PLASTIC
E-Z-HD barium sulfate FOR SUSPENSION;ORAL 208036 NDA E-Z-EM Canada Inc 32909-105 32909-105-10 24 BOTTLE, PLASTIC in 1 CASE (32909-105-10) / 148 g in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength98%
Approval Date:Jan 11, 2016TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength96%
Approval Date:Apr 7, 2017TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:FOR SUSPENSION;ORALStrength40%
Approval Date:Jan 3, 2017TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links